Ignite Creation Date:
2025-12-25 @ 3:24 AM
Ignite Modification Date:
2026-02-28 @ 7:29 AM
Study NCT ID:
NCT02716805
Status:
TERMINATED
Last Update Posted:
2022-10-12
First Post:
2016-03-02
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
Sponsor:
Ludwig Institute for Cancer Research
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
LUD2014-010
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None